Lilly opens new biotech innovation hub in San Diego

SAN DIEGO - Eli Lilly and Company (NYSE:LLY), a pharmaceutical giant with a market capitalization of $641.5 billion and impressive revenue growth of 37% over the last twelve months, on Friday opened its newest Lilly Gateway Labs (LGL) site in San Diego, expanding its network of innovation hubs designed to support early-stage biotechnology companies. According to InvestingPro data, Lilly maintains strong financial health with an industry-leading gross profit margin of 83%.

The 82,514-square-foot facility, located on the One Alexandria Square Megacampus in Torrey Pines, can accommodate up to 15 life sciences companies and more than 250 employees. The site was developed and is operated in partnership with Alexandria Real Estate Equities, Inc.

The San Diego location joins existing Gateway Labs in South San Francisco (two sites), Boston, and Beijing. According to the company, the Gateway Labs model provides startups with access to wet lab facilities, scientific engagement, and strategic guidance to help navigate drug discovery and development.

"The future of medicine depends on combining the strengths of academia, biotech and large pharma to solve some of the most difficult diseases facing patients," said Daniel Skovronsky, chief scientific officer and president of Lilly Research Laboratories and Lilly Immunology, in a press release statement.

Since the first Gateway Labs site opened in 2019, companies based at these facilities have raised more than $2 billion in capital and are developing over 50 therapeutics and platforms, according to Lilly. The company’s robust investment in innovation is backed by its strong financial position, with InvestingPro analysis showing the company has maintained dividend payments for 55 consecutive years and operates with a moderate level of debt. Investors seeking detailed insights into Lilly’s financial health and growth prospects can access the comprehensive Pro Research Report, available exclusively on InvestingPro.

The Gateway Labs initiative is part of Lilly Catalyze360, which also includes Lilly Ventures, Lilly ExploR&D, and Lilly TuneLab. Together, these programs aim to support biotech innovation through strategic capital, lab space, and R&D capabilities.

Several early-stage biotechs focused on next-generation treatment modalities have already established operations at the San Diego facility, which features flexibly designed laboratory and office space. Based on InvestingPro’s Fair Value analysis, Lilly’s stock currently appears fairly valued, with 14 analysts recently revising their earnings estimates upward for the upcoming period, suggesting continued strong performance ahead.

In other recent news, Eli Lilly has received FDA approval for Inluriyo, an oral treatment aimed at adults with specific types of advanced or metastatic breast cancer. The Phase 3 EMBER-3 clinical trial showed that Inluriyo reduced the risk of disease progression or death by 38% compared to standard endocrine therapy. Eli Lilly also announced plans to construct a $6.5 billion manufacturing facility in Houston, Texas, focusing on small molecule synthetic medicines. This facility is expected to create 615 permanent jobs and about 4,000 construction positions. In terms of analyst ratings, Bernstein has reiterated an Outperform rating on Eli Lilly with a price target of $1,100.00, citing confidence in the company’s oral GLP-1 medication. Cantor Fitzgerald also maintained an Overweight rating with a price target of $825.00, describing recent clinical trial data as "groundbreaking and practice changing." Additionally, Eli Lilly’s CEO has criticized the UK’s drug pricing, warning that the country may miss out on new medications if current conditions persist.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.